Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT

This journal article was triaged for T1 - Hematologic Malignancies based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with limited evidence maturity.

This journal article was triaged for T1 - Hematologic Malignancies based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with limited evidence maturity.

What the study was

Study design

Journal article

Maturity

Exploratory

Journal

Blood cancer journal

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.